10-Q: Biotricity Inc. Reports Improved Financial Performance in Q2 2025, Revenue Up 9.4% Year-Over-Year

Biotricity Inc. announced a 9.4% year-over-year increase in revenue for the six months ended September 30, 2024, alongside significant improvements in gross margin and operating expense management.

Summary

• Biotricity Inc. reported a revenue of $6.5 million for the six months ended September 30, 2024, a 9.4% increase compared to the same period last year.
• Technology fee revenue grew by 10.6% to $6.0 million, while device sales contributed $388 thousand.
• The company's gross profit margin improved to 74.6% from 66.2% year-over-year.
• Operating expenses decreased by 25.6% to $6.2 million, driven by reductions in selling, general, and administrative costs.
• Research and development expenses decreased to $1.0 million from $1.4 million in the prior year period.
• The company experienced a net loss of $5.3 million before dividends, an improvement from the $7.1 million loss in the same period last year.
• EBITDA improved by 80% and 50.4% for the three and six months ended September 30, 2024, respectively, compared to the corresponding prior periods.
• Adjusted EBITDA improved to negative $249 thousand for the quarter ended September 30, 2024, an 87% improvement year-over-year, and the company achieved a positive Adjusted EBITDA for the month of September 2024.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While there are significant improvements in revenue, gross margin, and operating expenses, the company still faces challenges with profitability, working capital, and a going concern warning. The positive trends and management's efforts to control costs and improve efficiency are encouraging, but the need for additional capital and the delisting from Nasdaq are concerning. Overall, the sentiment is cautiously optimistic.

Positives

• The company experienced a significant increase in revenue, driven by both technology fees and device sales.
• Gross profit margins improved substantially, indicating better cost management and pricing strategies.
• Operating expenses were significantly reduced, demonstrating improved efficiency and cost control.
• The company's Adjusted EBITDA showed a substantial improvement, indicating progress towards profitability.
• Biotricity achieved a positive Adjusted EBITDA for the month of September 2024, a significant milestone.

Negatives

• The company continues to operate at a net loss, although the loss has decreased compared to the previous year.
• Biotricity has a working capital deficit of $17.4 million as of September 30, 2024.
• The company was delisted from the Nasdaq Capital Market due to not meeting the minimum market value requirement.
• The company has a significant accumulated deficit of $136.1 million as of September 30, 2024.

Risks

• The company has a going concern warning, indicating substantial doubt about its ability to continue as a going concern.
• Biotricity needs to secure additional funding to support its operations and growth plans.
• The company's future financings may be dilutive to existing shareholders.
• There is no guarantee that the company will be able to raise additional capital on acceptable terms or at all.
• The company is not in compliance with certain covenants of its term loan, for which it sought and received relief from the term loan lender.

Future Outlook

The company anticipates continued revenue growth and improved liquidity through business development and additional financing. They expect to continue to devote significant resources to capital expenditures, research and development, marketing, and sales. The company believes its existing cash, along with anticipated near-term financings, will be sufficient to meet its needs for the next twelve months, but additional capital will be needed to respond to business opportunities and challenges.

Management Comments

• Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity and debt capitalization of the Company.
• Management considers the EBITDA and adjusted EBITDA measures for the three and six-month periods ended September 30, 2024, to be indicators of the Company's progress towards breakeven profitability as well as improvement towards operating cash-flow break-even.

Industry Context

The report highlights the growing importance of telemedicine and remote patient monitoring technologies, which aligns with broader industry trends. The company's focus on chronic cardiac disease prevention and management positions it well in a market with increasing demand for such solutions. The company is also leveraging AI to enhance its predictive capabilities, which is a key trend in the healthcare technology sector.

Comparison to Industry Standards

• While specific competitor data is not provided, the report indicates that Biotricity's technology has a large potential total addressable market, including hospitals, clinics, physicians' offices, and Independent Diagnostic Testing Facilities (IDTFs).
• The company's insourcing business model, which empowers physicians with state-of-the-art technology and charges technology service fees, is presented as a competitive advantage.
• The company's focus on recurring technology fee revenue is a common strategy in the medical technology industry, aiming for stable and predictable income streams.
• The company's development of AI-driven solutions aligns with the industry's move towards data-driven healthcare.
• The company's gross margin of 74.6% is a strong result, indicating a competitive position in the market.

Related Party Transactions

• Trade and other payables and accrued liabilities as at September 30, 2024 and March 31, 2024 included $307,085 and $837,945, respectively, due to a shareholder, who is a director and executive of the Company.

Stakeholder Impact

• Shareholders may be concerned about the company's going concern warning and the need for additional capital, which could dilute their holdings.
• Employees may be impacted by the company's cost-cutting measures and the uncertainty surrounding its financial stability.
• Customers may benefit from the company's improved technology and services, but may also be concerned about the company's long-term viability.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.
• Patients may benefit from the company's remote monitoring solutions, which can improve access to care and reduce healthcare costs.

Next Steps

• The company plans to continue to grow its sales force to address new markets and achieve sales penetration in the markets currently served.
• The company intends to continue to develop a telemedicine platform with real-time streaming capabilities.
• The company plans to continue to develop and seek regulatory approvals for new technologies.
• The company will need to seek additional debt or equity capital to respond to business opportunities and challenges.

Key Dates

Keywords

Biotricity, remote patient monitoring, cardiac monitoring, medical technology, Bioflux, Biocore, Biocare, telemedicine, FDA clearance, EBITDA, Adjusted EBITDA, revenue growth, gross margin, operating expenses, convertible notes, preferred stock, financial results